Bioavailability & Solubility Capabilities Updates
-
Quotient Sciences Capabilities Update November 2026: Bioavailability And Solubility
11/18/2026
Poor solubility can stall promising drugs. See how emerging human PK data can refine formulations, improve exposure, and accelerate development decisions.
-
Almac Pharma Services Capabilities Update November 2026: Bioavailability And Solubility
11/18/2026
Optimize bioavailability with biorelevant solubility, dissolution, and in vitro permeability testing to guide bioenhancement strategies and formulation development.
-
Upperton Pharma: Capabilities Update November 2026: Bioavailability/ Solubility
11/17/2026
Poor solubility can limit clinical success. Learn how API-sparing screening, spray-dried dispersions, and lipid-based systems accelerate lead formulation selection.
-
Jabil Capabilities Update November 2026: Bioavailability/ Solubility
11/17/2026
Poorly soluble oral drugs risk low clinical exposure. Learn how in silico modeling, nanosuspension technologies, and integrated testing accelerate formulation development and scale-up.
-
Ardena Capabilities Update November 2026: Bioavailability/ Solubility
11/17/2026
Boost bioavailability of poorly soluble oral drugs with data-driven formulation, modeling, micro-prototyping, and scalable manufacturing from early development through commercialization.